Edition:
India

Syngene International Ltd (SYNN.NS)

SYNN.NS on National Stock Exchange of India

615.80INR
19 Jan 2018
Change (% chg)

Rs24.20 (+4.09%)
Prev Close
Rs591.60
Open
Rs592.75
Day's High
Rs620.00
Day's Low
Rs590.50
Volume
188,308
Avg. Vol
150,788
52-wk High
Rs620.00
52-wk Low
Rs430.10

Latest Key Developments (Source: Significant Developments)

Bristol-Myers and Syngene expand ongoing research collaboration
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Syngene International ::Bristol-Myers Squibb and Syngene International expand ongoing research collaboration.Says collaboration with Bristol-Myers Squibb extended until 2026​.  Full Article

Syngene International ‍expands collaboration with Bristol-Myers Squibb​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Syngene International Ltd ::Says ‍expanded collaboration with Bristol-Myers Squibb​.Nnext phase of partnership will see addition of facility to support future Bristol-Myers Squibb research and development operations​.  Full Article

India's Syngene International Sept-qtr profit rises 3 pct
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Syngene International Ltd :Sept quarter net profit 769 million rupees versus profit of 747 million rupees last year.Sept quarter revenue from operations 3.35 billion rupees versus 3.03 billion rupees last year.  Full Article

Syngene International says no loss of life at lab fire
Tuesday, 13 Dec 2016 

Syngene International Ltd :Syngene International Ltd says fire last night at one laboratory building; no loss of life or any injury.  Full Article

Syngene International June-qtr profit rises
Thursday, 21 Jul 2016 

Syngene International Ltd : June-quarter net profit 598 million rupees versus 466 million rupees last year . June-quarter net sales 2.69 billion rupees versus 2.28 billion rupees last year . Two new facilities are now operational-first phase of Syngene research centre and a viral testing facility .  Full Article

BRIEF-Syngene International ‍expands collaboration with Bristol-Myers Squibb​

* Nnext phase of partnership will see addition of facility to support future Bristol-Myers Squibb research and development operations​ Source text: http://bit.ly/2iT2tvz Further company coverage: